- Home
- FRO vs VKTX Comparison
FRO vs VKTX Comparison
Compare FRO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRO
- VKTX
- Stock Information
- Founded
- FRO 1985
- VKTX 2012
- Country
- FRO Cyprus
- VKTX United States
- Employees
- FRO N/A
- VKTX N/A
- Industry
- FRO Marine Transportation
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FRO Consumer Discretionary
- VKTX Health Care
- Exchange
- FRO Nasdaq
- VKTX Nasdaq
- Market Cap
- FRO 3.6B
- VKTX 3.4B
- IPO Year
- FRO N/A
- VKTX 2015
- Fundamental
- Price
- FRO $15.03
- VKTX $23.91
- Analyst Decision
- FRO Strong Buy
- VKTX Strong Buy
- Analyst Count
- FRO 3
- VKTX 11
- Target Price
- FRO $27.33
- VKTX $95.18
- AVG Volume (30 Days)
- FRO 2.8M
- VKTX 3.7M
- Earning Date
- FRO 02-28-2025
- VKTX 04-23-2025
- Dividend Yield
- FRO 11.79%
- VKTX N/A
- EPS Growth
- FRO N/A
- VKTX N/A
- EPS
- FRO 2.23
- VKTX N/A
- Revenue
- FRO $2,050,385,000.00
- VKTX N/A
- Revenue This Year
- FRO N/A
- VKTX N/A
- Revenue Next Year
- FRO $12.01
- VKTX N/A
- P/E Ratio
- FRO $6.67
- VKTX N/A
- Revenue Growth
- FRO 13.77
- VKTX N/A
- 52 Week Low
- FRO $13.17
- VKTX $23.27
- 52 Week High
- FRO $29.39
- VKTX $81.86
- Technical
- Relative Strength Index (RSI)
- FRO 41.11
- VKTX 33.36
- Support Level
- FRO $14.28
- VKTX $23.27
- Resistance Level
- FRO $16.57
- VKTX $29.60
- Average True Range (ATR)
- FRO 0.48
- VKTX 1.52
- MACD
- FRO -0.10
- VKTX -0.38
- Stochastic Oscillator
- FRO 27.47
- VKTX 7.80
About FRO Frontline Plc
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.